Associate Professor Jemma Hopewell
|Tel||+44 (0)1865 743661|
- Genetic epidemiology of Lp(a), kidney function and vascular disease Research Group
- Using population biobanks and pharmacogenomics to enhance clinical trial design Research Group
- Investigating genetic and non-genetic determinants of heart rhythm Research Group
- Genetic determinants of chronic kidney disease and vascular risk Research Group
BSc (Hons) MSc PhD (Cantab)
Associate Professor & Senior Scientist in Genetic Epidemiology and Clinical Trials
- BHF Intermediate Basic Science Research Fellow
- MSc in Global Health Science Module Lead: Genetic Epidemiology
Associate Professor Jemma leads a medical statistics and genetic epidemiology team in a programme of research focusing on the use of genetic and clinical trial-based studies to investigate the causes and treatments for cardiovascular disease and arrhythmias. She has particular interests in determining predictors of patient response to therapy, using genetics to improve our understanding of drug targets and disease mechanisms, and genomic characterisation of vascular disease and its risk factors, particularly Lp(a). Jemma leads and collaborates on numerous projects involving CTSU's vascular mega-trials (e.g. HPS, SEARCH, THRIVE, REVEAL), large-scale studies and biobanks (e.g. PROCARDIS, UK Biobank), and international consortia (e.g. METASTROKE, CARDIoGRAMplusC4D, GoLEAD, CATCH-ME). She is a member of the Lp(a) Foundation Scientific Advisory Board, of various clinical trial and genetic study Steering and Analysis Committees, and is currently the Chair of METASTROKE (a collaboration of the International Stroke Genetics Consortium), as well as co-ordinating the MSc in Global Health Science Genetic Epidemiology module.
Association analyses based on false discovery rate implicate new loci for coronary artery disease.
Nelson CP. et al, (2017), Nat Genet
Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation.
Christophersen IE. et al, (2017), Nat Genet, 49, 946 - 952
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
Landray MJ. and REVEAL Collaborative Group None., (2017), American Heart Journal, 187, 182 - 190
No Association of Coronary Artery Disease with X-Chromosomal Variants in Comprehensive International Meta-Analysis.
Loley C. et al, (2016), Sci Rep, 6, 35278 - 35278
The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs
Mihaylova BN. et al, (2016), Circulation: Cardiovascular Quality and Outcomes